Literature DB >> 24870022

Exploring the roles of PALB2 at the crossroads of DNA repair and cancer.

Joris Pauty, Amélie Rodrigue, Anthony Couturier, Rémi Buisson1, Jean-Yves Masson.   

Abstract

PALB2 [partner and localizer of BRCA2 (breast cancer early-onset 2)] [corrected] has emerged as a key player in the maintenance of genome integrity. Biallelic mutations in PALB2 cause FA (Fanconi's anaemia) subtype FA-N, a devastating inherited disorder marked by developmental abnormalities, bone marrow failure and childhood cancer susceptibility, whereas monoallelic mutations predispose to breast, ovarian and pancreatic cancer. The tumour suppressor role of PALB2 has been intimately linked to its ability to promote HR (homologous recombination)-mediated repair of DNA double-strand breaks. Because PALB2 lies at the crossroads between FA, HR and cancer susceptibility, understanding its function has become the primary focus of several studies. The present review discusses a current synthesis of the contribution of PALB2 to these pathways. We also provide a molecular description of FA- or cancer-associated PALB2 mutations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24870022     DOI: 10.1042/BJ20140208

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  19 in total

Review 1.  Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.

Authors:  Trang H Au; Kai Wang; David Stenehjem; Ignacio Garrido-Laguna
Journal:  J Gastrointest Oncol       Date:  2017-06

2.  3D structure prediction of histone acetyltransferase proteins of the MYST family and their interactome in Arabidopsis thaliana.

Authors:  A V Raevsky; M Sharifi; D A Samofalova; P A Karpov; Y B Blume
Journal:  J Mol Model       Date:  2016-10-05       Impact factor: 1.810

3.  A PGAM5-KEAP1-Nrf2 complex is required for stress-induced mitochondrial retrograde trafficking.

Authors:  Gary B O'Mealey; Kendra S Plafker; William L Berry; Ralf Janknecht; Jefferson Y Chan; Scott M Plafker
Journal:  J Cell Sci       Date:  2017-08-24       Impact factor: 5.285

4.  Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma.

Authors:  Ching-Yao Yang; Jau-Yu Liau; Wei-Ju Huang; Yu-Ting Chang; Ming-Chu Chang; Jen-Chieh Lee; Jia-Huei Tsai; Yi-Ning Su; Chia-Cheng Hung; Yung-Ming Jeng
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

5.  RECQL: a new breast cancer susceptibility gene.

Authors:  Taraswi Banerjee; Robert M Brosh
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

Authors:  Marta Castroviejo-Bermejo; Cristina Cruz; Alba Llop-Guevara; Sara Gutiérrez-Enríquez; Mandy Ducy; Yasir Hussein Ibrahim; Albert Gris-Oliver; Benedetta Pellegrino; Alejandra Bruna; Marta Guzmán; Olga Rodríguez; Judit Grueso; Sandra Bonache; Alejandro Moles-Fernández; Guillermo Villacampa; Cristina Viaplana; Patricia Gómez; Maria Vidal; Vicente Peg; Xavier Serres-Créixams; Graham Dellaire; Jacques Simard; Paolo Nuciforo; Isabel T Rubio; Rodrigo Dienstmann; J Carl Barrett; Carlos Caldas; José Baselga; Cristina Saura; Javier Cortés; Olivier Déas; Jos Jonkers; Jean-Yves Masson; Stefano Cairo; Jean-Gabriel Judde; Mark J O'Connor; Orland Díez; Judith Balmaña; Violeta Serra
Journal:  EMBO Mol Med       Date:  2018-12       Impact factor: 12.137

Review 7.  Molecular and cellular functions of the FANCJ DNA helicase defective in cancer and in Fanconi anemia.

Authors:  Robert M Brosh; Sharon B Cantor
Journal:  Front Genet       Date:  2014-10-21       Impact factor: 4.599

8.  PALB2 mutations in breast cancer patients from a multi-ethnic region in northwest China.

Authors:  Yong Tao Li; Wei Hua Jiang; Xiao Wen Wang; Ming Shuai Zhang; Cheng Guang Zhang; Li Na Yi; Fulati WuwaliKhan; Aisikaer Ayoufu; Jiang Hua Ou
Journal:  Eur J Med Res       Date:  2015-10-21       Impact factor: 2.175

9.  Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer.

Authors:  Emmanuelle Nicolas; Sanjeevani Arora; Yan Zhou; Ilya G Serebriiskii; Mark D Andrake; Elizabeth D Handorf; Dale L Bodian; Joseph G Vockley; Roland L Dunbrack; Eric A Ross; Brian L Egleston; Michael J Hall; Erica A Golemis; Veda N Giri; Mary B Daly
Journal:  Oncotarget       Date:  2015-11-24

10.  Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction.

Authors:  Anthony M Couturier; Hubert Fleury; Anne-Marie Patenaude; Victoria L Bentley; Amélie Rodrigue; Yan Coulombe; Joshi Niraj; Joris Pauty; Jason N Berman; Graham Dellaire; Javier M Di Noia; Anne-Marie Mes-Masson; Jean-Yves Masson
Journal:  Nucleic Acids Res       Date:  2016-10-24       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.